Rxivist logo

Broadly protective vaccines against known and pre-emergent coronaviruses are urgently needed. Critical to their development is a deeper understanding of cross-neutralizing antibody responses induced by natural human coronavirus (HCoV) infections. Here, we mined the memory B cell repertoire of a convalescent SARS donor and identified 200 SARS-CoV-2 binding antibodies that target multiple conserved sites on the spike (S) protein. A large proportion of the antibodies display high levels of somatic hypermutation and cross-react with circulating HCoVs, suggesting recall of pre-existing memory B cells (MBCs) elicited by prior HCoV infections. Several antibodies potently cross-neutralize SARS-CoV, SARS-CoV-2, and the bat SARS-like virus WIV1 by blocking receptor attachment and inducing S1 shedding. These antibodies represent promising candidates for therapeutic intervention and reveal a new target for the rational design of pan-sarbecovirus vaccines. ### Competing Interest Statement AZW, DPM, MS, AL, JHN, EC, IB, MB, SL, MS, CJ, SP, LMW Are employees and equity holders in Adimab LLC

Download data

  • Downloaded 2,489 times
  • Download rankings, all-time:
    • Site-wide: 6,864
    • In immunology: 239
  • Year to date:
    • Site-wide: 20,481
  • Since beginning of last month:
    • Site-wide: 28,262

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide